HFA Icon

Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns

HFA Padded
Guest Post
Published on
Updated on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

Valeant Pharmaceuticals: SEC Subpoena, Arizona Targets Company and Jorn Resigns by TheSkeptic

If this week wasn’t bad enough for Valeant, Deb Jorn, the Executive Vice President and Company Group Chairman resigned today from the company. Ms. Jorn was responsible for all major US product launches as well as the Dermatology and GI therapeutic areas. These two areas were Valeant’s most important, representing HALF of Valeant’s forecasted 2016 US revenues. Moreover, Ms. Jorn was also responsible for the huge push of Dermatology products through the captive pharmacy channel they’d established with Philidor and it’s subsidiaries.

Philidor is basically in a world of shit, which could be why Ms. Jorn resigned. We know from an action...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article
Already a member? Log in here
HFA Padded

If you are interested in contributing to Hedge Fund Alpha on a regular or one time basis read this post